Ocular Therapeutix (OCUL) News Today → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free OCUL Stock Alerts $4.94 -0.26 (-5.00%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 6 at 12:51 PM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.3%Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.3%June 5 at 7:30 AM | globenewswire.comOcular Therapeutix® to Host Investor Day on June 13, 2024June 5 at 3:22 AM | americanbankingnews.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from BrokeragesJune 4, 2024 | globenewswire.comOcular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | seekingalpha.comOcular Therapeutix: Betting On Axpaxli For A Major Market BreakthroughJune 2, 2024 | americanbankingnews.comPiper Sandler Initiates Coverage on Ocular Therapeutix (NASDAQ:OCUL)June 1, 2024 | seekingalpha.comOcular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 ResultsMay 31, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Overweight Rating from Analysts at Piper SandlerPiper Sandler began coverage on Ocular Therapeutix in a research report on Friday. They issued an "overweight" rating and a $15.00 target price on the stock.May 29, 2024 | markets.businessinsider.comIcecure Medical: Strong Sales Growth and Promising Regulatory Prospects Underpin Buy RatingMay 29, 2024 | insidertrades.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $13,280.16 in StockMay 28, 2024 | marketbeat.comSanjay Nayak Sells 2,274 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 2,274 shares of the stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $5.84, for a total transaction of $13,280.16. Following the transaction, the insider now owns 178,026 shares of the company's stock, valued at approximately $1,039,671.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 28, 2024 | marketbeat.com4,500,159 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Franklin Resources Inc.Franklin Resources Inc. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,500,159 shares of the biopharmaceuticaMay 15, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading 7.8% Higher Ocular Therapeutix (NASDAQ:OCUL) Trading 7.8% HigherMay 15, 2024 | finance.yahoo.comOcular Therapeutix Inc Reports First Quarter 2024 EarningsMay 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong ProspectsMay 8, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) PT Lowered to $14.00 at HC WainwrightHC Wainwright dropped their target price on Ocular Therapeutix from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday.May 7, 2024 | washingtonpost.comOcular Therapeutix: Q1 Earnings SnapshotMay 7, 2024 | investorplace.comOCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comOcular Therapeutix™ Reports First Quarter 2024 ResultsMay 7, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2024 | markets.businessinsider.comOcular Therapeutix is about to announce its earnings — here's what to expectMay 6, 2024 | globenewswire.comOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $6.17Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $6.17May 6, 2024 | msn.comEyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goalMay 5, 2024 | stockhouse.comOcular Therapeutix(TM) To Present at Two Ophthalmology Meetings, May 4-9, 2024May 3, 2024 | globenewswire.comOcular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024May 2, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading 10% Higher Ocular Therapeutix (NASDAQ:OCUL) Trading Up 10%May 1, 2024 | globenewswire.comOcular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024April 26, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 10.7%Ocular Therapeutix (NASDAQ:OCUL) Shares Up 10.7%April 24, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 5% Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5%April 24, 2024 | fool.com2 Small-Cap Growth Stocks With Room To RunApril 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD PotentialApril 19, 2024 | msn.comBaird sees weakness in Ocular shares as "overdone"April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)April 19, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Sees Strong Trading VolumeOcular Therapeutix (NASDAQ:OCUL) Sees Large Volume IncreaseApril 19, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Ocular Therapeutix in a report on Friday.April 18, 2024 | marketwatch.comOcular Therapeutix Shares Dive on Axpaxli Trial ResultsApril 18, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 9.2%Ocular Therapeutix (NASDAQ:OCUL) Shares Down 9.2%April 18, 2024 | markets.businessinsider.comOcular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDRApril 18, 2024 | seekingalpha.comOcular marks early-stage trial win for diabetic retinopathy candidateApril 18, 2024 | globenewswire.comOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathyApril 17, 2024 | theglobeandmail.comAge-related Vision Dysfunction Market Size in the 7MM is anticipated to increase by 2032, estimates DelveInsightApril 17, 2024 | uk.investing.comOcular Therapeutix appoints new CEO amid leadership shiftApril 17, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79April 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)April 16, 2024 | markets.businessinsider.comThe Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 ExpertsApril 16, 2024 | marketbeat.comJMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix (NASDAQ:OCUL)JMP Securities reaffirmed a "market outperform" rating and issued a $24.00 target price on shares of Ocular Therapeutix in a research report on Tuesday.April 16, 2024 | stockhouse.comOcular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 16, 2024 | finance.yahoo.comOcular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 15, 2024 | marketbeat.comShort Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Increases By 28.9%Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 11,810,000 shares, a growth of 28.9% from the March 15th total of 9,160,000 shares. Based on an average daily volume of 2,050,000 shares, the days-to-cover ratio is presently 5.8 days. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Time is Running Out - June 25th Deadline Approaching! (Ad)If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay. See all the details you need here. OCUL Media Mentions By Week OCUL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.240.73▲Average Medical News Sentiment OCUL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼73▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARQT News Today PLRX News Today PHAT News Today INVA News Today TBPH News Today KNSA News Today KPTI News Today SUPN News Today IDYA News Today FOLD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored